Frenlosirsen
Based on 1 Customer Validation
Frenlosirsen (ION-935918; ION251) is an antisense oligonucleotide and also an IRF4 inhibitor. Frenlosirsen inhibits the survival of malignant plasma cells, reduces the burden of myeloma progenitor cells and prevents disease recurrence. Frenlosirsen is applicable to myeloma-related research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 96.46%
- CAS No.: 2304711-81-5
- Formule: C177H226N63O89P15S15
- Masse moléculaire:5605.63
-
Stockage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Activité biologique
Frenlosirsen (28-day dosing cycle, intravenous infusion, maximum dose of 660 mg) shows no dose-limiting toxicity and only mild drug-related adverse events in a Phase 1a clinical study of relapsed/refractory multiple myeloma[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 2304711-81-5
-
Appearance Solid
-
Masse moléculaire 5605.63
-
Formule C177H226N63O89P15S15
-
Color White to off-white
-
SMILES
[Frenlosirsen]
-
Synonyms
ION-935918; ION251
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Pureté et documentation
-
Fiche technique (265 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2242 KB)
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)